Here are six observations:
1. Revenue increased 13.2 percent in the second quarter of 2017, compared to the same period the year prior, hitting $282.2 million.
2. The company’s second quarter GAAP gross margin rose 80 basis points to 64.9 percent compared to the second quarter of 2016.
3. The second quarter GAAP net income fell to $10.8 million, due to acquisition and integration expenses.
4. Integra LifeSciences’ operating cash flow was valued at $28.9 million, reflecting a decrease from the same period the year prior.
5. The company updated its 2017 revenue guidance to a range of $1.125 billion to $1.14 billion.
6. Additionally, Integra LifeSciences’ is updating its 2017 full-year organic sales growth to between 6 percent and 7 percent.
More articles on devices:
Spinal Kinetics hits 50k+ procedures with M6 cervical, lumbar discs: 4 key notes
Smith & Nephew partners with Memphis medical device accelerator: 5 takeaways
Providence Medical Technology receives Australian regulatory approval: 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
